Safety and Efficacy of Oral DMSA Therapy for Children with Autism Spectrum Disorders: Part A - Medical Results

[Guest guest]

Even thou this is for treating heavy metals what about other toxins, like

mycotoxins?

Published:

23 October 2009

Abstract (provisional)

 

Background

This study investigated the effect of oral dimercapto succinic acid (DMSA)

therapy for children with autism spectrum disorders ages 3-8 years.

 

Methods

Phase 1 involved 65 children who received one round of DMSA (3 days).

Participants who had high urinary excretion of toxic metals were selected to

continue on to phase 2. In phase 2, 49 participants were randomly assigned in a

double-blind design to receive an additional 6 rounds of either DMSA or placebo.

 

Results

DMSA greatly increased the excretion of lead, substantially increased

excretion of tin and bismuth, and somewhat increased the excretion of thallium,

mercury, antimony, and tungsten. There was some increase in urinary excretion of

essential minerals, especially potassium and chromium. The Phase 1 single round

of DMSA led to a dramatic normalization of RBC glutathione in almost all cases,

and greatly improved abnormal platelet counts, suggesting a significant decrease

in inflammation.

 

Conclusions

Overall, DMSA therapy seems to be reasonably safe, effective in removing

several toxic metals (especially lead), dramatically effective in normalizing

RBC glutathione, and effective in normalizing platelet counts. Only 1 round (3

days) was sufficient to improve glutathione and platelets. Additional rounds

increased excretion of toxic metals.

[Guest guest]

sounds pretty interesting,

a fast way to bring down toxin bodyload ?

>

> Even thou this is for treating heavy metals what about other toxins, like

mycotoxins?

>

>

>

>

> Published:

> 23 October 2009

> Abstract (provisional)

>  

>

> Background

> This study investigated the effect of oral dimercapto succinic acid (DMSA)

> therapy for children with autism spectrum disorders ages 3-8 years.

>  

> Methods

> Phase 1 involved 65 children who received one round of DMSA (3 days).

> Participants who had high urinary excretion of toxic metals were selected to

> continue on to phase 2. In phase 2, 49 participants were randomly assigned in

a

> double-blind design to receive an additional 6 rounds of either DMSA or

placebo.

>

>  

> Results

> DMSA greatly increased the excretion of lead, substantially increased

> excretion of tin and bismuth, and somewhat increased the excretion of

thallium,

> mercury, antimony, and tungsten. There was some increase in urinary excretion

of

> essential minerals, especially potassium and chromium. The Phase 1 single

round

> of DMSA led to a dramatic normalization of RBC glutathione in almost all

cases,

> and greatly improved abnormal platelet counts, suggesting a significant

decrease

> in inflammation.

>  

> Conclusions

> Overall, DMSA therapy seems to be reasonably safe, effective in removing

> several toxic metals (especially lead), dramatically effective in normalizing

> RBC glutathione, and effective in normalizing platelet counts. Only 1 round (3

> days) was sufficient to improve glutathione and platelets. Additional rounds

> increased excretion of toxic metals.

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>